Nevertheless, the dual-blockade of CD39 and CD73, in combination with αPD-1/αCytotoxic T lymphocyte-associated protein-4 (CTLA-4) was successful in promoting robust anti-tumour T cell immunity in known therapy-resistant cancer models [107]. The gene discussed is NT5E; the disease is cancer.